Should I Buy GRAL? GRAL 2026 Analysis

Should You Buy Grail Inc (GRAL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

99.570

1 Day change

-5.55%

52 Week Range

118.840

Analysis Updated At

2026/01/29

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Grail Inc. (GRAL) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company has significant potential in the cancer detection market, its financial performance, technical indicators, and lack of immediate trading signals suggest that waiting for further developments or a better entry point may be prudent.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 45.033, showing no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 105.105, suggesting resistance ahead. Key support is at 95.234, and resistance is at 114.976.

Options Data

Bullish

Open Interest Put-Call Ratio

Neutral

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

The Galleri test's submission to the FDA, supported by positive PATHFINDER 2 study results, could enhance the company's market position.
Analysts have raised price targets, with Guggenheim recently increasing it to $
Revenue growth of 26.32% YoY in Q3 2025 shows expanding adoption of the Galleri test.

Neutral/Negative Catalysts

Financial performance remains weak, with net income down 29.21% YoY and EPS dropping 37.56%.
Gross margin is negative at -37.94%, down 51.11% YoY, indicating operational inefficiencies.
MACD and RSI suggest no strong upward momentum in the short term.
No recent congress trading data or significant hedge fund/insider activity to indicate strong institutional confidence.

Financial Performance

In Q3 2025, revenue increased by 26.32% YoY to $36.19 million, but net income dropped by 29.21% YoY to -$88.98 million. EPS fell by 37.56% YoY to -2.46, and gross margin declined to -37.94%, down 51.11% YoY. The company continues to burn cash but expects to sustain operations until 2030.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are generally positive on Grail, with Guggenheim raising its price target to $130 and maintaining a Buy rating. Canaccord and Morgan Stanley have also raised price targets, citing the long-term potential of the Galleri test. However, concerns remain about regulatory approvals and Medicare reimbursement.

3 Analyst Rating

Wall Street analysts forecast GRAL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRAL is 60.86 USD with a low forecast of 38 USD and a high forecast of 83.71 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 105.420

Low

Averages

60.86

High

83.71

Current: 105.420

Low

Averages

60.86

High

83.71

Guggenheim

Buy

upgrade

$100 -> $130

AI Analysis

2026-01-26

Reason

Guggenheim

Price Target

$100 -> $130

AI Analysis

2026-01-26

upgrade

Buy

Reason

Guggenheim raised the firm's price target on Grail to $130 from $100 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.

Canaccord

Kyle Mikson

Buy

maintain

$85 -> $105

2025-11-17

Reason

Canaccord

Kyle Mikson

Price Target

$85 -> $105

2025-11-17

maintain

Buy

Reason

Canaccord analyst Kyle Mikson raised the firm's price target on Grail to $105 from $85 and keeps a Buy rating on the shares. The firm target increase is driven by significant progress/plans to expand adoption levels (and reimbursement) for the Galleri multi-cancer early detection (MCED) test.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GRAL

Unlock Now

GRAL Should I Buy

GRAL Should I Buy

Should You Buy Grail Inc (GRAL) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch